NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.

Published Date: 10 Jul 2023

A highly selective noncovalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor called pirtobrutinib has demonstrated promise in a recent clinical trial.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

AI tool accurately detects tumor location on breast MRI

2.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

3.

Liver cancer survival rates reflect income disparities

4.

How cancer misinformation exploits the way we think

5.

Hemihedral resection not necessary for neuroendocrine surgery after appendicitis


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot